NDV-3 investigational vaccine
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Staphylococcal Infections
Conditions
Staphylococcal Infections, Candidiasis
Trial Timeline
Jan 1, 2011 → Dec 1, 2011
NCT ID
NCT01273922About NDV-3 investigational vaccine
NDV-3 investigational vaccine is a phase 1 stage product being developed by United Therapeutics for Staphylococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01273922. Target conditions include Staphylococcal Infections, Candidiasis.
What happened to similar drugs?
4 of 5 similar drugs in Staphylococcal Infections were approved
Approved (4) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01273922 | Phase 1 | Completed |
Competing Products
20 competing products in Staphylococcal Infections